Using multivariate analysis on PFS in the multimodal cohort, alterations of EGFR (n = 22/247, 8.9%; adjusted hazard ratio (aHR) = 2.14, 95% CI 1.06–4.31, P = 0.03), STK11 (n = 44/247, 17.8%; aHR = 2.53, 95% CI 1.71–3.74, P < 0.005) and tumor mutation burden (TMB) (median 7 mt per mb, range 0–90; aHR = 0.14, 95% CI 0.02–0.88, P = 0.04) exhibited significant aHR in a multivariable analysis of mutated oncogenes (EGFR, ALK, ROS1, RET, MET, ERBB2 and BRAF), tumor suppressor genes (STK11), transcription regulator (ARID1A) and TMB (Fig. 4a). This evidence concerns the gene ERBB2 and neoplasm.